Business
Bruker Reports Third Quarter 2025 Financial Results
Q3 2025 revenues of $860.5 million, down 0.5% year-over-year (yoy), down 4.5% organically Q3 2025 GAAP diluted loss per share $(0.41); non-GAAP diluted
About this update from Bruker Corporation
[{"type":"text","content":"\n\nQ3 2025 revenues of $860.5 million, down 0.5% year-over-year (yoy), down 4.5% organically\n\n\n\nQ3 2025 GAAP diluted loss per share $(0.41); non-GAAP diluted earnings per share (EPS) $0.45\n\n\n\nUpdated FY2025 guidance:\n\n\nRevenue $3.41 to $3.44 billion; reported growth of 1-2% yoy, organic decline of 4-5%\n\n\n\nNon-GAAP EPS $1.85 to $1.90\n\n\n\n\n\n\n \n\n\n BILLERICA, Mass.--(BUSINESS WIRE)--\nBruker Corporation (Nasdaq: BRKR) today announced financial results for the three and nine months ended September 30, 2025.\n\n\nFrank H. Laukien, Bruker’s President and CEO, commented: “In the third quarter, we were encouraged by our mid-single digit percentage organic bookings growth year-over-year, with a Scientific Instruments segment book-to-bill ratio greater than 1.0. For the first time this year, we saw strength in bookings in the academic/government market segment, as well as improving biopharma and applied markets orders. Notably, our innovative spatial biology, proteomics and multiomics solutions launched at AGBT and ASMS are being well received by our biopharma and academic customers and enhance our leadership in enabling tools for drug discovery and disease biology research in the post-genomic era.”\n\n\nHe continued: “As forecasted, our third quarter revenues and earnings were down year-over-year, primarily due to weaker academic and research instruments demand in the first half of 2025. However, our Q3-25 non-GAAP financial performance was better than expected and represents a meaningful sequential step-up from Q2-25. Nonetheless, due to previous market weakness and EPS dilution from higher share count, we are lowering our FY2025 guidance. For FY2026, our major cost-savings initiatives are progressing well towards the high end of our $100 to $120 million cost-down targets and are expected to deliver significant operating margin expansion and EPS growth in 2026.”\n\n\nThird Quarter 2025 Financial Results\n\n\nBruker’s revenues for the third quarter of 2025 were $860.5 million, a decrease of 0.5% compared to $864.4 million in the third quarter of 2024. In the third quarter of 2025, revenues decreased 4.5% organically yoy, with constant-exchange rate (CER) revenue decreasing 3.4%. Revenue growth from acquisitions was 1.1%, while foreign currency translation had a favorable impact of 2.9% yoy.\n\n\nThird quarter 2025...